PV Bulletin

Extension of e-labelling to P and GSL medicines

The Health Sciences Authority's Therapeutic Products Branch announced an extension of electronic labelling to Pharmacy-only (P) and General Sale List (GSL) medicines, effective 30 June 2026.

Primary source: Health Sciences Authority (HSA) Singapore

PV Impact Brief

Urgency: HighConfidence: high

What changed

The extension of the e-labelling scheme to include Pharmacy-only (P) and General Sale List (GSL) medicines effective from 30 June 2026.

Why it matters

This initiative enhances digital access to product information and safety updates, thus improving the labeling workflows and requiring updates to registration and packaging processes for Marketing Authorization Holders (MAHs).

Action needed

Manufacturers must adjust labeling workflows to incorporate e-labelling mechanisms, such as QR codes, for P and GSL medicines by the stipulated date.

Relevant for
Regulatory Intelligence LeadLabeling LeadQPPV
Processes impacted
Labeling
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Regulatory Update / Notice
Policy status
new
Publication date
2026-06-30
Policy change
The Health Sciences Authority's Therapeutic Products Branch (TPB) announced an extension of electronic labelling (e-labelling) to Pharmacy-only (P) and General Sale List (GSL) medicines, effective 30 June 2026. This initiative follows the previous implementation for Prescription-only Medicines (POM) and aims to enhance digital access to product information.

Key changes

Extension of the e-labelling scheme to include P and GSL categories of therapeutic products. Manufacturers and registration holders can now provide product information through digital means (e.g., QR codes) instead of or in addition to physical leaflets for these categories.

Affected workflows

Labeling

Responsible groups

Regulatory AffairsLabeling OperationsPharmacovigilance

PV impact

Improved accessibility to the latest product information and safety updates for healthcare professionals and consumers. This affects labeling workflows and requires updates to registration and packaging processes for MAHs.

View regulator source

Source document details

Extracted documents

Unable to extract linked source document: https://www.googletagmanager.com/ns.html

Evidence and confidence

Confidence: highSource updated: Jun 30, 2026

Full briefing

Practical implication

Manufacturers must adjust labeling workflows to incorporate e-labelling mechanisms, such as QR codes, for P and GSL medicines by the stipulated date.

This regulatory update mandates that manufacturers and registration holders can provide product information through digital means, such as QR codes, for Pharmacy-only and General Sale List medicines, leading to improved accessibility for healthcare professionals and consumers.

What changed: The extension of the e-labelling scheme to include Pharmacy-only (P) and General Sale List (GSL) medicines effective from 30 June 2026.

Why it matters: This initiative enhances digital access to product information and safety updates, thus improving the labeling workflows and requiring updates to registration and packaging processes for Marketing Authorization Holders (MAHs).

Practical implication: Manufacturers must adjust labeling workflows to incorporate e-labelling mechanisms, such as QR codes, for P and GSL medicines by the stipulated date.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Labeling#Safety Signals#new#policy-change#firecrawl-policy-agent#Regulatory Update / Notice#Health Sciences Authority (HSA) Singapore

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Atellica CH Revised C-Reactive Protein (RCRP) Safety Information - Siemens Healthcare Diagnostics

Urgency: High

Laboratories must implement the safety measures as indicated by the action registration number R2625739, effective from the notice date of September 7, 2026.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward